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ABSTRACT
Lung tumors represent a major health problem. In early stage NSCLC tumors, 
surgical resection is the preferred treatment, but 30-55% of patients will relapse 
within 5 years after surgery. Thus, the identification of prognostic biomarkers in early 
stage NSCLC patients, especially those which are therapeutically addressable, is crucial 
to enhance survival of these patients. We determined the immunohistochemistry 
expression of key proteins involved in tumorigenesis and oncogenic signaling, p53, 
EGFR, pAKT and pERK, and correlated their expression level to clinicopathological 
characteristics and patient outcome. We found EGFR expression is higher in the 
squamous cell carcinomas than in adenocarcinomas (p=0.043), and that nuclear p53 
staining correlated with lower differentiated squamous tumors (p=0.034). Regarding 
the prognostic potential of the expression of these proteins, high pERK levels proved 
to be an independent prognostic factor for overall (p<0.001) and progression-free 
survival (p<0.001) in adenocarcinoma patients, but not in those from the squamous 
histology, and high p53 nuclear levels were identified as independent prognostic 
factor for progression-free survival (p=0.031) only in squamous cell carcinoma 
patients. We propose a role as early prognostic biomarkers for pERK protein levels 
in adenocarcinoma, and for nuclear p53 levels in squamous cell lung carcinoma. 
The determination of these potential biomarkers in the adequate histologic context 
may predict the outcome of early stage NSCLC patients, and may offer a therapeutic 
opportunity to enhance survival of these patients.
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INTRODUCTION
Lung tumors represent a major health problem, 
accounting for most cancer-related deaths and with a 
5-year survival rate of only 18% after diagnosis [1]. Lung 
cancer is a heterogeneous disease and is classified into two 
major groups: small-cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC) [2]. NSCLC is the most 
common histology of lung cancer, representing 85% of 
lung cancer cases and is sub-classified as adenocarcinoma, 
squamous cell lung cancer and large cell carcinoma. 
Surgical resection plays a major role in the therapy of 
early-stage NSCLC tumors. After resection, recurrence, 
which occurs in up to 30-55% of patients at 5 years post-
surgery, and the appearance of distant metastases will 
determine the outcome [3-5]. Thus, the identification of 
prognostic biomarkers in early-stage NSCLC patients, 
especially those which are therapeutically addressable, is 
crucial to enhance survival of these patients.
There is evidence that different molecular alterations 
underlie phenotypic differences in NSCLC. These 
alterations are clinically relevant, and some of them 
represent feasible targets, with therapeutic implications 
[6]. In this sense, lung cancer patients harboring EGFR 
mutations are sensitive to EGFR tyrosine kinase inhibitors 
(TKIs) [7]. Although these mutations are characteristic 
of adenocarcinoma tumors [8, 9], it has been recently 
shown that some squamous cell carcinoma patients 
respond to anti-EGFR therapy [10] and that high EGFR 
expression levels correlate with better responses in these 
patients [11], highlighting the therapeutic relevance 
of EGFR in this setting. Alterations in EGFR, as well 
as in other genes such as KRAS mutations or ALK 
translocations, are frequent in lung adenocarcinoma; all 
these changes have been involved in the activation of 
signaling pathways critical in lung tumorigenesis, such as 
MAPK and PI3K/AKT pathways [12-14]. In the MAPK 
pathway, the phosphorylation of p42/p44 (ERK) is central, 
leading to their translocation to the nucleus, where they 
act as transcription factors and activate the expression 
of genes related to cell proliferation, anti-apoptosis, 
differentiation, migration and angiogenesis [15, 16]. In 
the PI3K/AKT pathway, the most important effector is 
AKT, whose phosphorylation leads to the activation of 
downstream proteins, which trigger pro-survival signaling, 
inhibit several repressors of cell cycle, and induce the 
transcription of pro-angiogenic genes [17].
On the other hand, the role of p53 is crucial in 
tumor suppression. When active, this protein binds to 
DNA and induces the expression of genes leading to 
cell cycle arrest and apoptosis. However, mutant p53 is 
unable to bind DNA and can no longer prevent cell cycle 
continuation, which contributes to cancer progression 
[18]. Furthermore, mutant p53 cannot be efficiently 
degraded and accumulates in the nucleus; thus, its protein 
levels can be easily detected [19]. To elucidate the role of 
these pathways in the tumorigenesis of NSCLC, we have 
determined the protein expression levels of key players 
in NSCLC, including EGFR, pAKT, pERK, and p53, as 
prognostic biomarkers in early-stage NSCLC.
RESULTS
Correlation of pAKT, pERK, nuclear p53 and 
EGFR protein levels and clinicopathological 
features
This study involved a cohort of 248 NSCLC 
patients with early-stage NSCLC, who were surgically 
resected (Table 1). Most patients were men (94.0%) 
with a median age of 66 years [interquartile range 39-
84], with a generally good performance status (ECOG 
0-1 in 96.3% patients). Most of them were current or 
ex-smokers (48.4% and 45.6%, respectively), while only 
4.4% were never-smokers. Considering the histology, 
49.6% and 31.0% cases belonged to the most prevalent 
lung cancer subtypes, squamous cell lung carcinoma 
and adenocarcinoma, respectively; 8.9% cases were 
diagnosed as large cell carcinomas; and 10.4% were 
identified as other histologic subtypes. Most tumors 
showed modest differentiation, with 39.4% and 31.5% of 
tumors classified as poorly or moderately differentiated, 
respectively, while only 7.3% of tumors showed high 
differentiation levels. Most tumors were diagnosed at 
stage I (56.9%) or II (27.8%), and only 14.9% cases 
were diagnosed at stage IIIA. Following radical surgery, 
12.1% patients received adjuvant radiotherapy, and 9.7% 
patients received adjuvant chemotherapy. Adjuvant 
chemotherapy was offered to patients with resected stage 
II and III NSCLC and in some patients with resected 
stage IB disease and a primary tumor larger than 4 cm. 
During the time of patient monitoring, 48.0% patients 
relapsed and 61.7% died, the most frequent cause for 
death being tumor progression. Baseline characteristics of 
the patients with adenocarcinoma (N=77) and squamous 
cell carcinoma (N=124) from this cohort are shown in 
Table 2. The clinicopathological characteristics of both 
adenocarcinoma and squamous cell carcinoma cohorts 
were similar. Differences between the two patient subsets 
were observed only in gender distribution (p=0.008); in 
the smoking status of patients, with a higher percentage of 
current smokers and a lower percentage of never-smokers 
in the squamous cell carcinoma cohort (p=0.024); and 
in tumor differentiation levels, with a higher percentage 
of poorly differentiated tumors in the squamous cell 
carcinoma cohort (p<0.001).
We determined the protein levels of pAKT, pERK, 
nuclear p53 and EGFR by IHC in the tumor samples of the 
entire stage I-IIIA NSCLC cohort and related them to the 
clinical information available. EGFR staining was positive 
in 69.9% of samples, and higher levels of this protein were 
associated with the squamous tumor histology (p=0.043, 
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odds ratio of 2.222, 95% CI 1.207-3.993, Table 3, Figure 1). 
pAKT staining was detected in 68.7% of samples, but no 
association was observed between this result and clinical 
features. When the squamous-cell-carcinoma-patient 
cohort was independently analyzed (Table 4), a correlation 
was observed between pERK and smoking habits, with a 
high pERK IHC score observed in a lower percentage of 
current smokers (p=0.030, odds ratio of 0.425, 95% CI 
0.188-0.959), compared with the remaining squamous 
cell carcinoma patients (Table 4). Nuclear p53 staining 
was detected in 97.2% of samples, and a correlation 
was observed between higher percentage of nuclear p53 
staining and lower tumor differentiation when the entire 
cohort was analyzed (p=0.01, odds ratio of 2.002, 95% CI 
1.207-3.323, Table 3). However, when we analyzed the 
adenocarcinoma- and squamous-cell-carcinoma-patient 
subsets independently, this correlation was only detected 
in the squamous cell carcinoma tumors (p=0.034, odds 
ratio of 2.109, 95% CI 1.011-4.400, Table 4) but not in the 
adenocarcinoma samples under study (p=0.188, Table 5). 
In addition, a correlation was observed between age and 
nuclear p53 levels within adenocarcinoma patients, with 
older patients showing a decreased percentage of nuclear-
p53-positive staining (p=0.018, odds ratio of 0.356, 95% CI 
0.135-0.938, Table 5).
Role of pAKT, pERK, nuclear p53 and EGFR 
protein levels as prognostic biomarkers in early-
stage NSCLC
We aimed to evaluate if the protein levels of our 
candidate biomarkers could be potential prognostic 
markers in early NSCLC; therefore, we correlated our 
IHC data with the clinical outcome information. When 
the entire NSCLC cohort was analyzed, no association 
was observed between nuclear pAKT or EGFR levels and 
survival in the univariate analysis (Supplementary Figures 
1-2). However, higher pERK levels correlated with worse 
progression-free (p=0.026) and overall (p<0.001) survival, 
with median progression-free survivals of 20.3 [11.8-
28.8] versus 54.9 [34.6-70.0] months and median overall 
survivals of 30.5 [16.3-44.6] versus 56.1 [35.4-76.8] 
months for patients with high- and low-pERK-staining 
tumors, respectively, when the entire NSCLC cohort was 
considered. When the squamous cell carcinoma patient 
cohorts were independently analyzed, no association 
of pERK levels with patient outcome was observed. 
However, when only the adenocarcinoma patient cohort 
was studied, a clear correlation was reported between 
higher pERK levels and worse progression-free (p=0.006) 
and overall (p=0.001) survival, with median progression-
free survival not reached in the low-pERK-level group 
vs 14.5 [4.4-24.6] months in the high-pERK-level group 
and a median overall survival of 62.6 [21.9-103.3] versus 
17.7 [7.5-28.0] months, respectively (Figure 2). When 
we analyzed the association between patient survival and 












 Ex smoker 113(45.6%)
 Current smoker 120(48.4%)
 Never smoker 11 (4.4%)
Histology
 Squamous cell carcinoma 123 (49.6%)
 Adenocarcinoma 77 (31.0%)
 Large cell carcinoma 22 (8.9%)
 Other 26 (10.4%)
Stage
 IA 27 (10.9%)
 IB 114 (46.0%)
 IIA 4 (1.6%)
 IIB 65 (26.2%)
 IIIA 37 (14.9%)
Tumour differentiation
 Well differentiated 18 (7.3%)
 Moderately differentiated 78 (31.5%)
 Poorly differentiated 98 (39.4%)
Adjuvant radiotherapy
 Yes 30 (12.1%)
 No 205 (82.7%)
Adjuvant chemotherapy
 Yes 24 (9.7%)
 No 213 (85.9%)
Relapse
 Yes 119 (48.0%)
 No 109 (44.0%)
Exitus
 Yes 153 (61.7%)
 No 76 (30.6%)
Reason for Exitus
 Progression 104 (41.9%)
 Not related 22 (8.9%)
 Undetermined 107 (43.1%)
 Surgical complications 4 (1.6%)
 Toxicity 10 (4.0%)
 Second tumour 1 (0.4%)
Continuous variables are expressed as median [interquartile 
range] and categorical variables are expressed as the number of 
cases (percentage).
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Table 2: Clinicopathological characteristics of the ADC and the SCC patient subsets in the NSCLC cohort
Variable ADC (N=77) SCC (N=124) p-value
Gender
Male 69 (89.6%) 122 (98.4%)
Female 8 (10.4%) 2 (1.6%) p=0.008
ECOG Performance status
0 50 (64.9%) 82 (66.1%)
1 24 (31.2%) 36 (29.0%)
2 1 (1.3%) 2 (1.6%) p=0.945
Age 63 [40–81] 67 [41–84] p=0.857
Smoking habits
Ex smoker 35 (45.5%) 56 (45.2%)
Current smoker 34 (44.2%) 66 (53.2%)
Never smoker 6 (7.8%) 1 (0.8%) p=0.024
Stage
IA 5 (6.5%) 20 (16.1%)
IB 42 (54.4%) 48 (38.7%)
IIA 1 (1.3%) 3 (2.4%)
IIB 18 (23.4%) 32 (25.8%)
IIIA 10 (13.0%) 21 (16.9%) p=0.130
Tumour differentiation
Well differentiated 11 (14.3%) 5 (4.9%)
Moderately differentiated 26 (33.8%) 49 (39.5%)
Poorly differentiated 24 (31.2%) 63 (50.8%) p<0.001
Adjuvant radiotherapy
Yes 11 (14.3%) 14 (11.3%)
No 63 (81.8%) 101 (81.5%) p=0.373
Adjuvant chemotherapy
Yes 10 (13.7%) 7 (6.0%)
No 63 (57.1%) 110 (94.0%) p=0.062
Relapse
Yes 40 (51.9%) 59 (47.6%)
No 33 (42.9%) 53 (42.7%) p=0.448
Exitus
Yes 48 (62.3%) 80 (64.5%)
No 26 (33.8%) 32 (25.8%) p=0.216
Continuous variables are expressed as median [interquartile range] and categorical variables are expressed as the number of 
cases (percentage).
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Table 3: Association between protein levels of pAKT, pERK, nuclear p53, and EGFR and clinicopathological 








0-1 2-3 0-1 2-3 0-1 2-3 <10% ≥10%
Gender**
 Male 109 (94.8) 123(93.2) 105 (94.6) 122 (93.1) 157 (91.8) 70 (98.6) 114 (92.7) 130 (94.9)
 Female 6 (5.2) 9 (6.8) 6 (5.4) 9 (6.9) 14 (8.2) 1 (1.4) 9(7.3) 7(5.1)
p-value p=0.401 p=0.422 p=0.035 NS
Age**
 <66 yo 53 (46.1) 66 (50.0) 58 (52.3) 59 (45.0) 85 (49.7) 32(45.1) 60(48.8) 67(48.9)
  ≥66 yo 62 (53.9) 66 (50.0) 53 (47.7) 72 (55.0) 86 (50.3) 39(54.9) 63(51.2) 70(51.1)
p-value p=0.313 p=0.161 p=0.303 NS
ECOG**
 0 81 (72.3) 86 (66.7) 71 (67.0) 93 (71.5) 118(71.1) 46(65.7) 83(68.6) 88(66.2)
 Rest 31 (27.7) 43 (33.3) 35 (33.0) 37 (28.5) 48 (28.9) 24(34.3) 38(31.4) 45(33.8)
p-value p=0.209 p=0.269 p=0.252 NS
Smoking 
habits**
  Current 
smoker
50 (43.5) 69 (52.3) 54 (48.6) 63 (48.1) 86 (50.3) 31(43.7) 62(50.4) 63(46.0)
 Rest 65 (56.5) 63 (47.7) 57 (51.4) 68 (51.9) 85 (49.7) 40(56.3) 61(49.6) 74(54.0)
p-value p=0.105 p=0.517 p=0.212 NS
Histology**
 SCC 41 (50.6) 82 (69.5) 53 (58.2) 67 (63.8) 86 (63.2) 34 (58.6) 56(50.5) 73(59.8)
 ADC 40 (49.4) 36 (30.5) 38 (41.8) 38 (36.2) 52 (37.7) 24(41.4) 55(49.5) 49(40.2)
p-value p=0.043 p=0.257 p=0.371 NS
Tumor 
differentiation**
 Poor 48 (41.7) 49 (37.1) 38 (34.2) 58 (44.3) 63 (36.8) 33(46.5) 39(31.7) 66(48.2)
 Rest 67 (58.3) 83 (62.9) 73 (65.8) 73 (55.7) 108 (63.2) 38(53.5) 84(68.3) 71(51.8)
p-value p=0.271 p=0.072 p=0.106 p=0.01
Stage**
 I 67 (58.3) 73 (55.3) 59 (53.2) 77 (58.8) 92 (53.8) 44(62.0) 66(53.7) 71(51.8)
 II/III 48 (41.7) 59 (44.7) 53 (46.8) 54 (41.2) 79 (46.2) 27(38.0) 57(46.3) 66(48.2)
p-value p=0.367 p=0.227 p=0.153 NS
Categorical values are expressed as number of cases (percentage)
*p-values were obtained using the Chi-square test. p-values are considered significant when lower than 0.05.
** IHC staining about some cases on these variables was not available.
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nuclear p53 percentage from the IHC data (Figure 3), no 
association was found in the entire NSCLC cohort nor 
in the adenocarcinoma-patient subset. However, in the 
squamous cell carcinoma patients, a clear association 
was found between higher nuclear p53 percentage and 
worse progression-free survival (p=0.031), with a median 
progression-free survival of 35.4 [22.7-48.1] months for 
patients with high nuclear p53 staining, while the median 
survival value was not reached in the group of patients 
with low nuclear p53 protein levels.
In multivariate analysis performed in the entire 
cohort (Table 6), stage and ECOG performance status were 
found to be independent prognostic factors in progression-
free (p=0.001 and p=0.010, respectively) and overall 
(p<0.001 and p=0.001, respectively) survival, as expected, 
as well as pERK levels (p=0.010 for progression-free and 
p<0.001 for overall survival). In the adenocarcinoma 
patient subset, the stage was reported as an independent 
prognostic factor, correlating with poorer progression-free 
(p=0.006) and overall (p=0.017) survival. Patient smoking 
habits and administration of adjuvant radiotherapy were 
identified as well to have an independent negative 
prognostic role in adenocarcinoma patients (Table 6), 
with respect to progression-free (p=0.001 and p=0.004, 
respectively) and overall (p=0.036 and p=0.006, 
respectively) survival, as well as pERK levels (p<0.001 
and p<0.001, respectively). In multivariate analysis of 
the squamous-cell-carcinoma-patient subset (Table 6), 
ECOG demonstrated an independent prognostic role in 
progression-free (p=0.003) and overall (p=0.001) survival. 
Nuclear p53 protein levels proved to be an independent 
prognostic factor in the squamous histology patient cohort, 
with respect to progression-free survival (p=0.031).
In addition, we studied the association of the 
expression of these proteins with the response to 
adjuvant chemotherapy. To this aim, we performed 
subset analysis in stage II-III patients as previously 
described [20]. By incorporating the expression levels 
of the previously assessed proteins into chemotherapy 
treatment information, we identified a trend demonstrating 
that patients with high nuclear pAKT expression could 
benefit from adjuvant chemotherapy; however, this 
therapeutic approach may not be a good choice for 
patients whose tumors show low expression of this 
marker (Supplementary Figure 3A). A contrasting trend 
was observed in the case of pERK levels; patients whose 
tumors showed high expression of pERK exhibited shorter 
survival times in the adjuvant chemotherapy arm, while 
low pERK expression in tumors correlated with better 
outcomes after adjuvant chemotherapy administration 
(Supplementary Figure 3B). However, these results did not 
reach statistical significance. This finding may be due to 
the low number of patients under adjuvant chemotherapy 
treatment in our cohort (9.7%, Table 1), which additionally 
precluded the feasibility of performing these analyses 
separating by tumor histology. For the other two proteins 
under study (EGFR and p53), however, we did not find 
any association of their expression to chemotherapy 
response (Supplementary Figure 4A-4B).
DISCUSSION
In this study, we report a prognostic role for pERK 
levels in lung adenocarcinoma, and we demonstrate that 
nuclear p53 expression is a potential prognostic biomarker 
in lung squamous cell carcinoma patients, where it is 
associated with poorer tumor differentiation.
Within our early-stage NSCLC cohort, we analyzed 
the differences between the adenocarcinoma- and the 
squamous-cell-carcinoma-patient subsets to prevent any 
influence from important variations between the subsets 
on our conclusions. We observed that gender distribution 
between the subsets was different, with almost all women 
located in the adenocarcinoma subset. However, this is 
possibly due to the low number of women in our cohort (15 
women versus 233 men). Furthermore, we found differences 
Figure 1: Representative images of the different IHC detection patterns of EGFR in squamous cell carcinoma and 
adenocarcinoma patients.
Oncotarget19951www.oncotarget.com
in the smoking habits of the patients, with a higher 
proportion of former or current smokers in the squamous 
cell carcinoma subset, compared to the adenocarcinoma 
subset. This is consistent with the literature, as squamous 
cell carcinoma has been linked to heavy smoking [21, 22]. 
We observed that tumors in the squamous cell carcinoma 
cohort showed poorer differentiation than those from 
the adenocarcinoma subset, but this may be an intrinsic 
characteristic of squamous cell carcinoma, as reported in 
other cohorts [23, 24]. No differences in other important 
clinicopathological variables were observed.
When we analyzed the relationships between 
pAKT, pERK, p53 and EGFR levels and clinical 
data, we observed that the squamous cell carcinoma 
tumors showed higher EGFR protein levels. EGFR 
has been primarily linked to adenocarcinoma, where 
alterations in this gene represent a cancer-driving 
force, and anti-EGFR therapy is approved for patients 
Table 4: Association between protein levels of pAKT, pERK, nuclear p53, and EGFR and clinicopathological 








0-1 2-3 0-1 2-3 0-1 2-3 <10% ≥10%
Gender**
 Male 48 (98.0) 73 (98.6) 53 65 (97.0) 85 (98.8) 33(97.1) 51 (98.1) 67 (98.5)
 Female 1 (2.0) 1 (1.4) (100.0) 2 (3.0) 1 (1.2) 1 (2.9) 1 (1.9) 1 (1.5)
p-value p=0.640 0 (0.0) p=0.310 p=0.488 p=0.681
Age**
 <66 yo 19 (38.8) 36 (48.6) 24 (45.3) 30 (44.8) 43 (50.0) 11(32.4) 27 (51.9) 27 (39.7)
  ≥66 yo 30 (61.2) 38 (51.4) 29 (54.7) 37 (55.2) 45 (50.0) 23 67.6) 25 (48.1) 41 (60.3)
p-value p=0.186 p=0.551 p=0.060 p=0.126
ECOG**
 0 34 (72.3) 48 (66.7) 30 (60.0) 50 (75.8) 0 (72.3) 20 60.6) 35 (70.0) 45 (68.2)
 Rest 13 (27.7) 24 (33.3) 20 (40.0) 16 (24.2) 23 (27.7) 13 (39.4) 15 (30.0) 21 (31.8)
p-value p=0.328 p=0.054 p=0.157 p=0.499
Smoking habits**
Current smoker 23 (46.9) 42 (56.8) 27 (50.9) 37 (55.2) 51 (59.3) 13 38.2) 29 (55.8) 35 (51.5)
 Rest 26 (53.1) 32 (43.2) 26 (49.1) 30 (44.8) 35 (40.7) 21 61.8) 23 (44.2) 33 (48.5)
p-value p=0.189 p=0.389 p=0.030 p=0.389
Tumor 
differentiation**
 Poor 27 (55.1) 35 (47.3) 22 (41.5) 39 (58.2) 41 (47.7) 20(58.8) 21 (40.4) 40 (58.8)
 Rest 22 (44.9) 39 (52.7) 31 (58.5) 28 (41.8) 45 (52.3) 14(41.2) 31 (59.6) 28 (41.2)
p-value p=0.254 p=0.051 p=0.185 p=0.034
Stage**
 I 27 (55.1) 41 (55.4) 28 (52.8) 38 (56.7) 45 (52.3) 21(61.8) 28 (53.8) 38 (55.9)
 II/III 22 (44.9) 33 (44.6) 25 (47.2) 29 (43.3) 41 (47.7) 13(38.2) 24 (46-2) 30 (44.1)
p-value p=0.560 p=0.405 p=0.232 p=0.485
Categorical values are expressed as number of cases (percentage)
*p-values were obtained using the Chi-square test. p-values are considered significant when lower than 0.05.
** IHC staining about some cases on these variables was not available.
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with these alterations. However, anti-EGFR therapy 
has proven efficacy in patients with the squamous 
cell carcinoma histology as well [10, 11]. Our data 
suggest that, although EGFR molecular alterations 
are not as frequent in squamous cell carcinoma as in 
adenocarcinoma, high expression of this gene occurs in 
the squamous cell carcinoma and may be the reason for 
anti-EGFR therapy being efficacious in some squamous 
cell carcinoma patients [11].
Regarding the prognostic potential of our candidate 
biomarkers, we found a prognostic role for the assessment 
of pERK nuclear levels in our early-stage NSCLC 
cohort. pERK levels have been observed to correlate with 
advanced staging, lymph node involvement and tumor size 
in NSCLC-patient cohorts including tumors at all stages 
[25, 26]. In several retrospective studies involving NSCLC 
patients, high pERK levels were reported as a prognostic 
factor for overall survival [26, 27] and for recurrence-
Table 5: Association between protein levels of pAKT, pERK, nuclear p53, and EGFR and clinicopathological 








0-1 2-3 0-1 2-3 0-1 2-3 0-1 2-3
Gender**
 Male 36 (90.0) 32(88.9) 35 (92.1) 33 (86.8) 44 24(100.0) 34(85.0) 33(94.3)
 Female 4 (10.0) 4 (11.1) 3 (7.9) 5 (13.2) (84.6) 0 (0.0) 6 (15.0) 2 (5.7)
p-value p=0.583 p=0.356 8 (15.4) p=0.07 p=0.179
Age**
 <66 yo 25 (62.5) 19(52.8) 24 (63.2) 20 (52.6) 30(57.7) 14 (58.3) 18(45.0) 25(71.4)
  ≥66 yo 15 (37.5) 17(47.2) 14 (36.8) 18 (47.4) 22(42.3) 10 (41.7) 22(55.0) 10(28.6)
p-value p=0.266 p=0.243 p=0.580 p=0.018
ECOG**
 0 28 (71.8) 22(62.9) 26 (72.2) 24 (63.2) 36(72.0) 14 (58.3) 28(70.0) 21(63.6)
 Rest 11 (28.2) 13(37.1) 10 (27.8) 14 (36.8) 14(28.0) 10 (41.7) 12(30.0) 12(36.4)
p-value p=0.284 p=0.280 p=0.181 p=0.372
Smoking habits**
 Current 
smoker 16 (40.0) 17(47.2) 19 (50.0) 14 (36.8) 21(40.4) 12 (50.0) 18(45.0) 14(40.0)
 Rest 24 (60.0) 19(52.8) 19 (50.0) 24 (63.2) 31(59.6) 12 (50.0) 22(55.0) 21(60.0)
p-value p=0.344 p=0.177 p=0.295 p=0.420
Tumor 
differentiation**
 Poor 14 (35.0) 9 (25.0) 10 (26.3) 13 (34.2) 15(28.8) 8 (33.3) 10(25.0) 13(37.1)
 Rest 26 (65.0) 27(75.0) 28 (73.7) 25 (65.8) 37(71.2) 16 (66.7) 30(75.0) 22(62.9)
p-value p=0.243 p=0.309 p=0.444 p=0.188
Stage**
 I 25 (62.5) 21(58.3) 20 (52.6) 26 (68.4) 32(61.5) 14 (58.3) 24(60.0) 22(62.9)
 II/III 15 (37.5) 15(41.7) 18 (47.4) 12 (31.6) 20(38.5) 10 (41.7) 16(40.0) 13(37.1)
p-value p=0.446 p=0.120 p=0.492 p=0.494
Categorical values are expressed as number of cases (percentage)
*p-values were obtained using the Chi-square test. p-values are considered significant when lower than 0.05.
** IHC staining about some cases on these variables was not available.
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Figure 2: Overall and progression-free Kaplan-Meier survival curves for the entire NSCLC patient cohort and for the 
squamous cell carcinoma (SCC) and adenocarcinoma (ADC) patients, attending to the pERK score, as assessed by 
IHC. Scores of 0 and 1 were considered as “low”, and scores of 2 or 3 were considered as “high”.
Oncotarget19954www.oncotarget.com
Figure 3: Overall and progression-free Kaplan-Meier survival curves for the entire NSCLC patient cohort and for 
the squamous cell carcinoma (SCC) and adenocarcinoma (ADC) patients, attending to the nuclear p53 percentage, 
as assessed by IHC. Percentages less than 10% were considered as “low”, and percentages equal to or above 10% were considered as 
“high”.
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free survival [28]. In these studies, unlike in our study, 
early- and late-stage tumors, adenocarcinomas and 
squamous cell carcinomas were jointly analyzed. In line 
with these results, when we analyzed our entire cohort, 
a prognostic role for pERK was observed in these early-
stage tumors; however, further analysis by us revealed that 
this effect is exclusive for adenocarcinoma and that the 
prognostic role of pERK in the entire cohort is possibly 
due to influence from the adenocarcinoma cohort. In the 
Asian cohorts previously reported, approximately 50% 
patients were diagnosed with adenocarcinoma, which is a 
higher percentage than that found in our cohort. This fact 
suggests that the prognostic effect of pERK for NSCLC, 
reported in these studies, may be due to the influence 
of adenocarcinoma tumors in these cohorts. The most 
incident molecular alterations in lung adenocarcinoma, 
namely, KRAS mutations, EGFR mutations and ALK 
translocations, have been linked to MAPK activation [12-
14]. Mutations in these three genes alone represent the 
driving alteration in approximately half of adenocarcinoma 
tumors [29], which is in accordance with the prognostic 
role of pERK observed in our adenocarcinoma cohort. 
Thus, our data suggest a potential central role for ERK 
in early-stage lung adenocarcinoma tumorigenesis and 
highlight a therapeutic potential for MEK inhibitors in 
these patients.
Additionally, we report a prognostic role for p53 
nuclear expression in the lung squamous cell carcinoma 
patients from our cohort. It has been reported that p53 
mutations confer stability to the protein and make 
it detectable by IHC staining [30-32]. The potential 
prognostic role of p53 immunostaining in NSCLC 
has been previously addressed in the literature, with 
controversial results. In multiple retrospective studies, 
no association was reported between high p53 expression 
and prognosis [33-36]. In these studies, adenocarcinoma, 
squamous cell carcinoma and other NSCLC histologies 
were jointly analyzed, which may explain that 
no prognostic potential could be reported for p53 
immunostaining, consistent with our analysis for the entire 
cohort. In contrast to the previously cited studies, another 
study correlated p53 IHC and poorer survival in NSCLC 
[37]. This study evaluated p53 IHC not only in primary 
lung tumor samples but also in metastatic tumors, and 
most samples were obtained from advanced-stage tumors 
(III-IV). Furthermore, the different histologies of NSCLC 
were analyzed together, the most prevalent histology 
being adenocarcinoma. This study suggests a potential 
prognostic role for p53 immunostaining in advanced and 
metastatic NSCLC. In the present study, however, we 
aimed to identify early prognostic biomarkers. Therefore, 
we analyzed primary, resectable tumors, mainly early-
Table 6: Multivariate analysis of variables independently affecting outcome in the whole cohort (N=248)
NSCLC (N=248) Adenocarcinoma (N=77) Squamous cell carcinoma (N=124)
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stage tumors. We aimed to evaluate different histologies 
of NSCLC independently, due to their distinct molecular 
nature. These different characteristics of the cited study 
and the present study may explain the differences in the 
results from these studies. In accordance with our results, 
a study involving stage I lung squamous cell carcinoma 
patients reported that high p53 IHC correlates with lower 
overall survival [38]. Our results in a higher number 
of patients, are in line with this prognostic role for p53 
IHC in lung squamous cell carcinoma and extend it to 
early-stage patients, and not only to stage I patients, with 
this subtype of NSCLC. Furthermore, we reported that 
high p53 immunostaining correlated with lower tumor 
differentiation when analyzing the entire NSCLC cohort; 
however, when we analyzed the adenocarcinoma and 
squamous cell carcinoma patient subsets independently, 
we observed that this correlation between p53 and tumor 
differentiation was only maintained in squamous cell 
carcinoma. p53 IHC staining has been previously related 
to poor differentiation in NSCLC [39]. Wild-type p53 
has been involved in differentiation [40, 41] through the 
suppression of NANOG expression in mouse embryonic 
stem cells. Furthermore, mutant p53 has been shown to 
exert differentiation-blocking effects, affecting normal 
cellular maturation and generating highly proliferative 
lethal tumors [42] and to facilitate reprogramming 
efficiency of somatic cells [43-45]. These data suggest that 
p53 may have a role in tumor differentiation in squamous 
cell carcinoma tumors, which may explain its prognostic 
role that we report in this context. Regarding the potential 
therapeutic relevance of these findings, although limited 
therapies addressing p53 alterations have been approved 
for use in patients, several approaches to target p53 are 
being evaluated [46]. Our data suggest that selected 
squamous cell carcinoma patients may benefit from these 
therapies.
On the other hand, the determination of genome-
wide mRNA expression in different NSCLC-patient 
cohorts has identified a number of prognostic multigene 
signatures stratifying early-stage NSCLC patients into 
different risk groups. In a recent large-scale meta-analysis 
comparing 42 published gene signatures in a large group 
of datasets, including 1927 NSCLC patients, the meta-
estimated hazard ratios (95% CI) for predicted high risk 
groups was observed to be between 1.25 and 1.72 in the 
cases of adenocarcinoma-based signatures and between 
1.25 and 1.41 for those signatures based on squamous cell 
carcinomas [47]. However, to date, only two multigene 
prognostic signatures have been commercialized and are 
currently under validation in prospective randomized 
controlled trials [48, 49]. These are myPlan® Lung Cancer 
(Myriad, Salt Lake City, UT) and Pervenio™ Lung RS 
platform (Life Technologies, West Sacrament, CA. Both 
signatures, focused on adenocarcinoma tumors, stratify 
patients into high- and low-risk groups with hazards 
ratios of approximately 1.5-2 [50, 51] and 2 [52, 53], 
respectively. However, we propose a simpler evaluation 
strategy (pERK in adenocarcinoma, and nuclear p53 in 
squamous cell carcinoma) for prognostic biomarkers 
using immunohistochemistry, a technique routinely 
performed in clinics and feasible in one FFPE sample 
sheet and thus requiring a very limited amount of tissue. 
Although validation in larger cohorts is required to 
confirm our results, our proposed prognostic marker for 
adenocarcinoma, pERK, shows an independent prognostic 
potential with a hazard ratio of approximately 4 in 
progression-free and overall survival. The result suggests 
that this single protein biomarker may predict effects 
more distinctly than either commercial gene signature. 
In addition, we propose p53 nuclear protein expression 
as a prognostic biomarker for early-stage squamous 
cell carcinoma tumors, a histologic subtype that may 
be excluded from these commercially available gene 
signature tests. This potential biomarker appears to predict 
a higher effect on prognosis, showing a hazard ratio of 
2 for progression-free survival, above the 1.4 maximum 
value reported for the squamous cell lung carcinoma gene 
signatures aforementioned [47].
In addition, we assessed the potential of the expression 
of the proteins under study in predicting the response to 
adjuvant chemotherapy. We observed a clear trend suggesting 
that only patients with tumors exhibiting high nuclear pAKT 
or low pERK expression may benefit from this treatment, 
while this therapy may not be a good option for tumors 
with the opposite characteristics. In line with these results, 
high pAKT levels have been linked to better response 
to neoadjuvant chemotherapy in breast cancer patients 
[54], and low pERK expression has been correlated with 
longer survival of NSCLC patients receiving neoadjuvant 
chemotherapy [55]. However, other retrospective studies 
have shown contrasting results, suggesting that high-pERK- 
and low-pAKT-expressing NSCLC tumors are the tumors 
that respond to adjuvant chemotherapy [28]. Nevertheless, 
our analyses regarding the predictive value of these markers 
did not reach statistical significance, probably due to the 
low number of patients receiving adjuvant chemotherapy 
in our cohort. Due to this limitation, these results should be 
carefully interpreted, and further studies need to be conducted 
involving cohorts with a higher number of patients to evaluate 
the potential predictive role of these two markers for adjuvant 
chemotherapy efficacy.
In conclusion, we propose the immunohistochemical 
determination of the protein expression of pERK and 
nuclear p53 as potential prognostic biomarkers in resected 
adenocarcinoma and squamous cell lung carcinoma 
tumors, respectively. Determination of the expression of 
these potential biomarkers in the appropriate histologic 
context, through a technique demanding low sample 
quantity and used routinely in the clinic, may define the 
outcome of early-stage NSCLC patients and may offer a 
therapeutic opportunity to enhance survival of patients 




The present study was performed in 248 early TNM 
stage (I-IIIA) subjects from the Virgen del Rocio Hospital 
(Seville, Spain), who had undergone surgical resection. 
Inclusion criteria were the following: (1) histologically 
confirmed diagnosis of early-stage NSCLC, (2) adequate 
clinical data recorded in medical charts, and (3) adequate 
tissue specimen available for immunohistochemistry 
(tissues were formalin-fixed and paraffin-embedded (FFPE) 
until further use). A written consent form for biobanking 
was obtained from all patients, and the study was approved 
by the Ethical Committee of the Virgen del Rocío Hospital.
Immunohistochemistry
Tumoral area from the FFPE samples was identified 
by pathologists following hematoxylin-eosin staining. 
Tissue microarrays (TMAs) were constructed with 
punches of 1 mm diameter and 3 mm length obtained from 
the preselected tumoral area from every biopsy. Tissue 
processing was performed, while protecting samples from 
oxidation and maintaining the integrity of each sample 
during the process. De-paraffination and antigenic epitope 
recovery was performed using the PTLinK kit (Dako 
Glostrup, Denmark). Immune detection was performed 
with the pAKT (Ser473, #736E11, Cell Signaling), pERK 
(Thr202/Tyr204, #9101 CST), FLEX p53 (#GA616, 
Dako) and EGFR (#NCL-L-EGFR-384, Leica) antibodies. 
Scoring of IHC staining is based on the criteria followed 
in a previous study [56], as presented in Supplementary 
Table 1.
Statistical analysis
Statistical analysis of clinical data and survival was 
performed with the SPSS statistical package (v19, IBM). 
The relationship between clinicopathological features and 
IHC data was analyzed using contingency tables, and p-value 
was obtained using the Chi-Square test. The magnitude of the 
effect is shown as odds ratio (OR) [95% confidence interval 
(CI)]. Kaplan-Meier overall survival (OS) and progression-
free survival (PFS) curves were defined, and significant 
differences were calculated by a Log Rank univariate 
analysis. In addition, multivariate analysis was performed 
with the Cox proportional hazards method. In these analysis, 
OS and PFS were defined as the time from diagnosis to exitus 
and progression, respectively. P-values below 0.05 were 
considered as statistically significant.
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